Gut microbiota analysis may help prevent the more serious effects of COVID-19. With this premise, Microviable seeks funding to design a predictive model and open the possibility of designing treatments from Spain.
“The analysis of a cohort of healthcare personnel, who have been very exposed to COVID-19, some of whom will have been infected and others will not have been infected, will let to assess the differences in its microbiota and the metabolites and see if the differences could have a modulating effect on COVID-19 infection”. Noelia Martinez, Director of R&D at Microviable.
View more at RTPA